For & Against

What's Next

The stock enters Q2 2026 with a dense operating calendar: Q1 earnings land in under three weeks, two quarters of wage-annualization reads follow, and a fresh €230M acquisition (Gleamer) starts delivering claimed synergies by Q3. Consensus expects a small GAAP loss against 18.6% revenue growth — so the disagreement will be visible in margin mix, not the top line. The next six months resolve more of the bull/bear gap than the prior twelve did.

No Results

Where the market is most likely to focus: imaging segment EBITDA margin on May 11 (wildfire/storm noise will be heavy, so the read is noisy — but the wage-scissors debate gets its first partial answer); Digital Health segment operating loss direction in absolute dollars (bull needs narrowing, bear needs widening, and the FY25 baseline is -$32.3M on $92.7M of revenue); and any new IPR&D impairment commentary on the 2024–2025 AI platforms (iCAD, See-Mode, CIMAR, Gleamer). Two quiet prints and the bull wins the setup by default; one buried charge and the bear case gets a second data point after Aidence.

For / Against / My View

For

**The multiple reset has already happened.** EV/EBITDA went from 21.9x (FY25 peak) to 14.5x while the stock fell from $93.65 to $56.44 — roughly 40% drawdown on a business whose revenue accelerated to 14.8% YoY in Q4 2025 and whose operating cash flow set a record $298.8M (+28% YoY). The market is now paying 14.5x for a business with a re-rated growth engine that it paid 22x for a year ago.

**Digital Health is a real platform, not a slide — and the moat is FDA-cleared.** DH revenue grew 41% YoY to $92.7M with customer count jumping from 486 to 2,075 and ARR ending FY25 at $75M, targeted to $140M by end-2026 (~85% growth). 22 FDA clearances — including iCAD's mammography stack with a 1,500-customer installed base — are commercially defensible because competing clearances take 2–3 years and clinical trials to replicate. This is regulatory-protected workflow software embedded in the largest outpatient imaging network in the U.S.

**Management credibility is elite on the part of the story that matters first.** Guidance was raised in 7 of the last 8 quarters. Q1 2025 wildfires/storms cost $22M revenue and $15M EBITDA — management pre-announced the exact hit when releasing Q4 2024, delivered the number to the dollar, and still raised full-year guidance. A 20+ year operating bench runs the imaging half; external hires from Philips and Siemens run the Digital Health half. Peers like DVA and SEM do not currently match that execution quality.

Bull price target: $85 over 12–15 months. Anchored on FY26E revenue $2.25B (10% growth), imaging EBITDA margin recovery to 17% post-wage-annualization → $382M EBITDA × 18x EV/EBITDA = $6,880M EV; net debt ~$323M → equity $6,560M / 78.5M shares. Disconfirming signal: DH YoY growth prints below 25% for two consecutive quarters, OR imaging EBITDA margin fails to recover above 16% by 3Q26.

Against

**Digital Health losses are doubling faster than revenue.** FY25 segment revenue grew 41% to $92.7M, but operating loss went from -$14.9M to -$32.3M — a 35% operating-loss margin at $93M of revenue, where 45% of revenue is still sold to RadNet itself. Management's bridge from $75M ARR (YE25) to $140M (YE26) requires 85% growth, most of it from iCAD/See-Mode/CIMAR customers not yet through a renewal cycle. The only product-level milestone RadNet has already attempted — Aidence's Veye lung-nodule IPR&D — was impaired for $3.9M in September 2023 after its FDA filing failed, disclosed inside the MD&A rather than on the call.

**The re-rate is already reversing, and the tape confirms it.** EV/EBITDA ran from ~9x to 22x in two years with the same operating margin — a pure multiple story. At 14.5x it still sits 1.3 standard deviations above the 20-year median of 8.5x, which is the anchor in a fundamentals-led derate. Price is 18.8% below the 200-day SMA, printed its second death cross in 13 months on 2026-03-20, and is 40% off the November 2025 high. Weighted diluted share count is up 33% since Q1 2023 (57M → 76M) to fund the AI strategy, so every re-rate dollar divides across a larger base.

**Succession cliff welded to a related-party lock.** Berger is 81, holds Chairman/CEO/President simultaneously, has no named successor, and directly owns just 0.66% of shares. He personally owns 99% of BRMG — the physician group that supplies doctors to nearly every California and Arizona RadNet center — under a management agreement auto-renewed for ten years on January 1, 2024, paying RadNet 78% of BRMG's collections. Adjacent disclosures are consistent with asymmetric downside: 11 open-market insider sales and zero buys over the last six months (-$9.3M) through a $60–82 price range; COO Patel with 177,649 shares pledged in a margin account; say-on-pay support 89% → 83%.

Bear downside target: $36 over 12–18 months. Revert EV/EBITDA to the 20-year historical median of ~10x on FY25 EBITDA of $314M ($3.14B EV), less $323M net debt ($2.82B equity), divided by 78.5M shares. Primary trigger: a Digital Health guide cut or ARR shortfall in Q2/Q3 FY26, or a second IPR&D impairment on a 2024–2025 acquired platform.

The Tensions

1. 14.5x EV/EBITDA: entry point or still expensive?

Bull says the multiple compressed 35% from 21.9x to 14.5x while operating cash flow set a record — the re-rating is done and the fair multiple sits closer to the 18x they apply in their target. Bear says 14.5x still sits 1.3 standard deviations above the 20-year median of 8.5x, so the compression has further to run toward a $36 reversion. Both cite the same current 14.5x figure. This resolves on the next two imaging EBITDA margin prints — Q1 2026 (May 11, noisy on storms) and Q2 2026 (August, first clean wage-annualization comp). Imaging EBITDA margin back above 17% defends the bull's 5-year-mean anchor; stuck near 15% pulls the multiple toward the bear's 20-year median.

2. Digital Health FY25 P&L: SaaS platform or capital sink?

Bull and bear both cite the same segment line: $92.7M revenue, -$32.3M operating income, 41% YoY growth. Bull reads it as a $75M ARR, 22-FDA-clearance, 2,075-customer platform whose losses are investment dollars against an $140M YE26 ARR target. Bear reads it as a business whose operating loss doubled at 45% intercompany revenue, with the one prior AI milestone (Aidence) already impaired. This resolves on two consecutive prints where (a) segment operating loss narrows in absolute dollars while revenue grows ≥40% YoY, and (b) external (non-intercompany) ARR grows >50% YoY ex-acquisition. Q2 and Q3 FY26 are the windows.

3. Management's disclosure record: disciplined operator or selective discloser?

Bull cites 7-of-8 guidance raises and the Q1 2025 wildfire pre-announcement that printed to the dollar. Bear cites the same team's Q3 2025 GAAP EPS miss by 65%, the Aidence IPR&D impairment buried in MD&A rather than called out, Berger's 99%-owned BRMG auto-renewal, and 11 insider sales / 0 buys / -$9.3M over six months through a $60–82 range. Both are describing the same management team's candor record. This resolves on Q1 2026 disclosure quality (May 11) — whether any integration charge on iCAD/See-Mode/CIMAR is pre-announced or buried — and on subsequent Form 4 activity through August.

My View

I'd lean cautious here — the Against side is modestly heavier, and the tension that tips the scale is the second one. The imaging half of the story is earned; the Digital Health half is not, and the segment operating loss doubling while bull and bear argue over the same $92.7M/-$32.3M line is the cleanest single-fact disagreement in the name. I'd wait for the Q2 2026 print (August) rather than anchor on the May 11 result, because Q1 will be too noisy on winter storms to settle the wage-scissors debate. The one data point that would flip the view is two consecutive quarters where the DH segment operating loss narrows in absolute dollars while revenue continues to grow ≥40% — that is the specific signal the bear case cannot absorb, and the specific signal the bull case requires. Until then, size small or stay out; the setup favors patience over conviction either way.